CTOs on the Move

Integrated Recovery Products

www.irpusa.com

 
Integrated Recovery Products is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.irpusa.com
  • 1945 Placentia Ave Ste c1
    Costa Mesa, CA USA 92627
  • Phone: 949.548.8314

Executives

Name Title Contact Details

Similar Companies

MedAccess

MedAccess is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health Dialog

Health Dialog is a total population healthcare services provider that offers risk-bearing entities (health plans, employers, and providers) an integrated suite of services driven by powerful analytics. These services include member engagement programs, multi-channel health coaching, medication adherence support, and shared decision making tools. We are part of the Rite Aid family. Through client partnerships and customized engagements, our dedicated team of healthcare professionals helps clients improve quality of care and reduce healthcare costs while empowering individuals to make informed health and wellness decisions.

All Care Visiting Nurse Association Of Greater Lynn Inc

All Care Visiting Nurse Association Of Greater Lynn Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Lynn, MA. To find more information about All Care Visiting Nurse Association Of Greater Lynn Inc, please visit www.allcarevna.org

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

Saint Peter's University Hospital

Saint Peter's University Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New Brunswick, NJ. To find more information about Saint Peter's University Hospital, please visit www.saintpetersuh.com